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ABSTRACT 
The global pharmaceutical sector is highly patent intensive, and firms rely on product, process and 
formulation patents to protect their innovations. Intellectual property rights on pharmaceutical 
products, as contained in the Agreement on Trade Related Aspects of Intellectual Property Rights 
(hereafter, the TRIPS Agreement) have been defended on grounds of extensive R&D investments 
required to discover and develop new drugs. But at the same time, grant of uniform pharmaceutical 
patents in all developing and least developed countries that are members of the World Trade 
Organization in accordance with the TRIPS Agreement, raises a range of issues for access to 
medicines. These issues can be framed under three broad areas: the restriction of reverse 
engineering possibilities for firms in developing countries and its implications for catch-up in this 
sector, higher prices of drugs and access to medicines as well as access to technologies due to 
patents on upstream technologies. The transitional arrangements under the TRIPS Agreement 
specifically mandated that all developing countries that are members to the WTO enact national 
laws that are TRIPS-compliant by 2005. As a result, from 2005 onwards, several countries like 
India, which played an important role as producers and exporters of generic copies of brand name 
products patented outside the country, can no longer produce such drugs due to the introduction of 
TRIPS-compliant patent regimes in their countries. Least developed countries have an extension 
until 2016 to implement the pharmaceutical patent provisions of the TRIPS Agreement under the 
Doha Declaration on TRIPS and Public Health. However, such legal flexibility is quite 
meaningless for least developed countries in the absence of local technological capabilities to 
produce generic drugs amongst least developed countries. 
Bangladesh, although a least developed country, is an exception in this regard with 
thriving domestic processing sectors that are actively engaged in producing textiles and 
ready made garments (RMGs), processed food products and generic drugs. Therefore, the 
question that looms large in the global access to medicines debate is whether 
Bangladesh’s pharmaceutical sector can gradually evolve to provide low-cost substitutes 
of important patented drugs to other developing and least developed countries? This 
study is an original empirical investigation into issues of innovative capacity and 
competitiveness of the local pharmaceutical sector in Bangladesh. 
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1. INTRODUCTION 
The global pharmaceutical sector is highly patent intensive, and firms rely on product, 
process and formulation patents to protect their innovations. Intellectual property rights on 
pharmaceutical products, as contained in the Agreement on Trade Related Aspects of 
Intellectual Property Rights (hereafter, the TRIPS Agreement) have been defended on 
grounds of extensive R&D investments required to discover and develop new drugs. But 
at the same time, grant of uniform pharmaceutical patents in all developing and least 
developed countries that are members of the World Trade Organization in accordance with 
the TRIPS Agreement, raises a range of issues for access to medicines. These issues can 
be framed under three broad areas: the restriction of reverse engineering possibilities for 
firms in developing countries and its implications for catch-up in this sector, higher prices 
of drugs and access to medicines as well as access to technologies due to patents on 
upstream technologies. 
The transitional arrangements under the TRIPS Agreement specifically mandated that all 
developing countries that are members to the WTO enact national laws that are TRIPS-
compliant by 2005. As a result, from 2005 onwards, several countries like India, which 
played an important role as producers and exporters of generic copies of brand name 
products patented outside the country, can no longer produce such drugs due to the 
introduction of TRIPS-compliant patent regimes in their countries. Least developed 
countries have an extension until 2016 to implement the pharmaceutical patent provisions 
of the TRIPS Agreement under the Doha Declaration on TRIPS and Public Health. 
However, such legal flexibility is quite meaningless for least developed countries in the 
absence of local technological capabilities to produce generic drugs amongst least 
developed countries. The Doha Declaration on the TRIPS Agreement and Public Health 
provides that developing countries like India can still continue to produce generic versions 
of patented drugs for consumption in least developed countries without manufacturing 
capabilities under compulsory licenses even after 2005. The 30th August 2003 Decision of 
the WTO contains a waiver on the TRIPS requirement that compulsory licensing is 
predominantly for the domestic market (Article 31), and provides the mechanism through 
which this can be actualized. In a further attempt, the 06 December 2005 Decision of the 
WTO transforms the waiver contained in the 2003 decision to be a permanent amendment 
to the TRIPS Agreement. A minimum of two-thirds of the WTO members are required to 
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ratify this change, for it to become a permanent amendment of the TRIPS Agreement. 
Until December 2007 which is the deadline for the ratification process, the waiver under 
the 30 August 2003 decision is in place. 
Bangladesh, although a least developed country, is an exception in this regard with 
thriving domestic processing sectors that are actively engaged in producing textiles and 
ready made garments (RMGs), processed food products and generic drugs. Therefore, the 
question that looms large in the global access to medicines debate is whether Bangladesh’s 
pharmaceutical sector can gradually evolve to provide low-cost substitutes of important 
patented drugs to other developing and least developed countries? This study is an original 
empirical investigation into issues of innovative capacity and competitiveness of the local 
pharmaceutical sector in Bangladesh. 
2. LEARNING, INNOVATION AND COMPETITIVENESS IN THE 
PHARMACEUTICAL SECTOR: DETERMINANTS AND GLOBAL TRENDS 
Innovation in the global pharmaceutical sector can easily be classified into two broad 
categories: the introduction of new chemical entities (NCEs) which relies extensively on 
R&D activities and incremental innovation activities, also called “imitative R&D”, or 
“me-too” drugs (Botazzi et al, 2001). Discovering new chemical entities is not just a 
matter of R&D capabilities; it involves extensive risk-taking, since the result is erratic and 
outcomes highly unpredictable. Only 154 new chemical entities have been introduced 
between 1975-1994 world wide, and although the search for blockbuster drugs is what 
drives the R&D process in pharmaceuticals (Grabowski, 2002), much of pharmaceutical 
innovation centres around the second category due to reasons of diversification of risk 
portfolios for the larger firms, and the lack of risk-taking abilities for most of the other 
firms worldwide. This second category of imitative R&D ranges from inventing around 
existing molecules, to creating new combinations of existing molecules, to discovering 
new ways of drug delivery (NDDS) as well as more direct generic drugs production 
(Botazzi et al, 2001). 
Generic manufacturing of pharmaceutical drugs further consists of two steps: the 
production of active pharmaceutical ingredients (APIs), which requires chemical synthesis 
skills and is commonly referred to as ‘reverse-engineering’ capabilities, and final 
formulations, which is a purely manufacturing activity and involves the mixing of active 
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pharmaceutical ingredients with other non-active ingredients into pill, tablets, or other 
forms of administration (Bumpas, 2007). 
2.1. Spectrum of Technological Capabilities for Pharmaceutical Innovation 
How firms fare in both NCE-based and on-NCE-based pharmaceutical innovation depends 
on their technological capabilities. These technological capabilities can be mapped along a 
spectrum, that begins with mere manufacturing skills that are required for formulation 
activities, and progresses to acquisition of chemical synthesis skills for reverse-
engineering the APIs, to more sophisticated generic competition in terms of new drug 
delivery systems (NDDS), or inventing around molecules, to finally being able to conduct 
NCE research at the frontier. Each stage is accompanied by learning activities of various 
kinds, and an innovative firm proceeds through all these stages of capabilities 
accumulation, from manufacture to more knowledge-based activities that begin with 
reverse engineering. This trajectory of capabilities accumulation is not peculiar to the 
pharmaceutical sector alone; firms across a variety of high technology and low technology 
sectors demonstrate similar behaviour (Oyeyinka and Gehl Sampath, Forthcoming). Table 
1 below contains a non-exhaustive list of countries that exhibit varying degrees of 
capabilities for pharmaceutical innovation. 
Table 1: Mapping technological capabilities in the pharmaceutical sector 
NCE research Imitative innovation Manufacture 
Requires extensive R&D 
capabilities at the frontier 
Requires extensive 
incremental innovation 
capabilities, including R&D  
Requires formulation skills 
Examples: USA, Germany, 
Switzerland, UK 
Examples: France, Italy, 
Japan, India, China 
Examples: Bangladesh, 
Kenya, Brazil 
    Source: Author; Botazzi et al (2001). 
Innovation from the viewpoint of the firm essentially comprises the practice and 
production of all product and process technologies that are new to them and their context 
and not necessarily to the universe (Nelson and Rosenberg, 1993). All activities at the firm 
level that enhance learning skills, expand the knowledge base and increase 
competitiveness both locally and globally, are innovative activities. R&D is one form of 
knowledge production, but such a definition of innovation includes also all other forms of 
activities through which firms access knowledge and technologies in order to progress 
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along the learning curve. The information and knowledge that form the primary inputs to 
technological learning and innovative capacity in firms, originate from within the firm and 
from outside (the knowledge system). 
2.2. Institutional Frameworks for Innovative Capacity and Competitiveness 
Firm-level capacity to absorb knowledge and apply it to innovation (Cohen and Levinthal, 
1990) is determined primarily by the extensive and complementary relationship between 
firms and the knowledge system in which they are embedded. How much and how fast 
firms’ in any sector transition to build technological capabilities to compete at the frontier 
depends on how well the institutional framework is geared towards promoting 
coordination within the various parts of the domestic knowledge system. Organizations 
such as universities (for human capital provision), financial institutions (for venture capital 
and financing of research), industrial infrastructure (for manufacturing products or 
acquiring information related to production), entrepreneurial associations (for marketing 
and assessment of market-based conditions), all provide incentives (or disincentives) for 
firms to tap knowledge sources, both internal and external.2 Institutional efficiency in such 
a context can thus be defined as how effectively access to knowledge for local firms can 
be achieved at minimal transaction costs, and is critical in explaining the process of 
knowledge sharing that underlines interactive learning and innovative success. 
In the pharmaceutical sector, the institutions for human skills formation (universities and 
centres of excellence for biomedical research), industrial infrastructure, regulatory policy 
for drugs, innovation incentives including appropriate intellectual property protection, and 
support policies for the enterprise sector are critical to enable learning and innovation 
activities. In developing country contexts, several limitations in the macro, meso and 
micro institutional environment limit the building of innovative capacity in the sector, and 
these are set out in Table 2 below. Therefore, achieving optimal coordination and 
performance amongst these institutions (and organizations that are created under them) is 
normally a predominant aim of industrial policy for the sector in countries that seek to 
promote technological capacity in the pharmaceutical sector (see Towse, 1995, among 
others). Additionally, recent evidence seems to point out unequivocally to the fact that the 
                                               
2
 Users (both domestic and foreign) as well as competing firms, especially those from outside the economy 
can also play important roles as providers of knowledge. 
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absence of intellectual property protection enables early stages of pharmaceutical 
innovation capacity, which comprises mainly of reverse engineering and imitative 
activities (Correa, 2004; 2007; Gehl Sampath; 2007). 
Table 2: Macro, meso and micro-level limitations in institutional frameworks 
Macro level limitations Meso level limitations Micro level limitations 
Disjuncture between demand for 
health research and on-going 
activities in the sector. 
 
Lack of scientific culture among 
scientists and researchers 
(including emphasis on 
collaboration). 
 
 
Bureaucratic rigidity and 
corruption. 
 
Weak public support. 
Lack of access to information 
and technological inputs. 
 
 
Weak scientific support 
infrastructure for universities, 
public research institutes and 
firms. 
 
 
Inadequate human capital 
formation 
 
Institutional instability 
Intellectual isolation of 
researchers 
 
 
Lack of incentives for 
collaborative research (e.g., 
low salaries, restriction of 
career opportunities, lack of 
on-job training, etc) 
 
 
Source: Author; adapted from CHDR (1990). 
Competitiveness is thus the outcome of these various institutions that impact upon 
performance and access to technologies for local firms. Cheap labour can be an aspect of 
competitiveness in sectors that thrive upon low cost technologies, like the textiles, agro-
processing but in the case of more sophisticated sectors like pharmaceuticals, labour can 
hardly be a determinant of competitiveness (Gehl Sampath, 2007). Climbing up the 
productivity or technological ladder requires rents/ subsidies in sectors attempting to 
catch-up (Noman and Stiglitz, 2007, p. 10). These rents, in order to be sustained over the 
mid-term or the long-term, need to accrue from value-added activities and not just labour. 
In the case of the pharmaceutical sector, this will involve the acquisition of new 
technologies and moving up the value chain. 
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2.3. Methodology 
This study is based on extensive primary research on the pharmaceutical sector in 
Bangladesh between May 2006 and May 2007, using both quantitative and qualitative 
techniques. The research process was detailed and consisted of three main stages; in the 
first stage, a background report and a pilot survey on the state of innovation and the main 
incentives that play a role in driving innovation in the pharmaceutical sector in 
Bangladesh was conducted jointly with a local research team. The second stage consisted 
of 130 firm-level surveys; guided by data generated through the background report and the 
pilot survey.  A total of 130 questionnaires were administered to firms, universities and 
public research institutes active in biomedical research and hospitals. The third stage 
consisted of face-to-face interviews conducted with a cross-section of firms, as well as a 
variety of other actors, such as professional associations and agencies and the concerned 
government departments. These detailed interviews have been used as case studies to 
interpret the results of the survey. A total of 68 persons (including CEOs, and top level 
management, and government officials) were interviewed for the study. 
In keeping with the framework for analysis, the study defined innovation as the 
application of new practices and production of all products and process technologies that 
are new to the firms in question (Nelson and Rosenberg, 1993). Innovation was measured 
by the number of new product and process development applied by the firms in the past 
five years. The study attempted to capture a realistic picture of innovation in the 
pharmaceutical sector, in order to understand the various factors that promote/hinder 
innovation, competitiveness and access to medicines issues, both for the local and global 
markets. In order to do so, the survey covered the enterprise sector, as well as public 
sector research institutions – namely, universities and public research institutes as well as 
hospitals. Amongst firms, the survey covered both indigenous pharmaceutical firms and 
subsidiaries of MNCs operating within the country, in addition to both public and private 
universities. Hospitals and medical practitioners often play a key role in generating 
demand for pharmaceutical innovations, as well as participate in research activities 
through training hospitals, in many countries. In order to assess these inter-linkages, the 
survey covered hospitals as well. A total of 45 firms, 43 university and public research 
institute respondents and 50 hospitals were surveyed all over the country for the survey. 
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Competitiveness of the firms is measured through indicators such as exports 
(manufacturing exports as a percentage of overall production of the firm), evolution of the 
sector over time (policies and institutions as well as response of the main sector actors), 
comparison among competences of different size classes (small, medium, large sized 
firms), observed rates of innovation, costs of production, including sources of machinery 
and production inputs (local and foreign) and other productivity figures. 
3. BANGLADESH: COUNTRY FACTS 
The domestic economy of Bangladesh is characterized largely by low technology 
endowments, dominance of trading and services in the absence of significant natural 
resource assets. In the 1970s and 1980s most of the economy relied on the agricultural 
sector for job creation due to lack of human resources and scientific and technological 
infrastructure and resulting low levels of industrial development. During the 1990s, liberal 
economic policies that emphasized labour-intensive manufacturing and agro-based 
industrial production have gradually focused attention on non-farm activities in the 
country (World Bank, 2005a). Policy reform was initiated through Structural Adjustment 
Programs and Enhanced Structural Adjustment Programs that were initiated in 1982, 
1985-1986 and then again in 1991-1992 (see Hossain and Karunarathne, 2002), which 
resulted in a unilateral trade liberalization of Bangaldesh’s economy (Dowlah, 2003). 
3.1. Knowledge Infrastructure 
Bangladesh has very weak knowledge infrastructure gauged by conventional indicators 
such as R&D investments as percentage of GDP, centres of excellence for basic and 
applied research in both the public and private sectors of the economy, and scientists and 
researchers per million of the population. Table 3 shows available education information 
for Bangladesh for the years 2000-2005, and Table 4 contains information on R&D 
investments as percentage of GDP and researchers per million, among others. As Table 3 
shows, Bangladesh’ success in terms of near-universal primary school enrolment (World 
Bank, 2005b), does not extend to secondary and tertiary education. There is a drastic drop 
in enrolment rates from primary to secondary and tertiary education, which draws a bleak 
picture of the human skills available in the country with severe repercussions for 
innovative capacity, a result that was corroborated by data collected in the survey. 
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Table 3: Education Indicators Bangladesh 2000-2005 
2000 2001 2002 2003 2004 2005
Education
School enrollment, primary (% gross) 109 108 107 106 109 NA
School enrollment, primary (% net) 89 90 91 93 94 NA
School enrollment, secondary (% gross) 50 51 52 51 NA NA
School enrollment, secondary (% net) 47 48 49 48 NA NA
School enrollment, tertiary (% gross) 6 7 6 7 NA NA
Pupil-teacher ratio, primary 57 55 56 54 NA NA
Source: World Development Indicators database, World Bank, 2007.  
 
There is no data available on researchers involved in R&D and data on R&D expenditure 
for the country is also not available since 2003. However, findings of several earlier 
investigations on LDCs help to gauge the situation. As UNCTAD (2006) notes, the gross 
expenditure on R&D in 2003 was 0.2 per cent of GDP in LDCs (about ten times less than 
in developed countries) and the number of researchers and scientists engaged in R&D 
activities per million population in 2003 were 2 per cent of the level observed in 
developed countries. 
Table 4: Investment and R&D in Bangladesh 2000-2005 
2000 2001 2002 2003 2004 2005
Investment and R&D
Foreign direct investment, net inflows (% of GDP) 1 0 0 1 1 -
Merchandise imports (current US$)* 8,883 9,018 8,592 10,434 12,023 13,868
Research and development expenditure (% of GDP) 1 1 1 - - -
Researchers in R&D (per million people) - - - - - -
Financial Support
Domestic credit to private sector (% of GDP) 26 27 29 29 30 32
Interest rate spread (lending rate minus deposit rate) 7 7 8 8 8 6
Market capitalization of listed companies (% of GDP) 3 2 3 3 6 5
* Amounts in 100,000
Source: World Development Indicators database, World Bank 2007.  
 
3.2. Present Patenting Regime in Bangladesh 
As a least developed country, Bangladesh is exempt from implementing the general 
provisions of the TRIPS agreement until 2013, and has an extension until 2016 to 
implement its provisions on pharmaceutical patents (in accordance with the Doha 
Declaration).3 However, the country is presently working towards gradual compliance 
with the TRIPS Agreement pursuant to a bilateral treaty with the EU that requires 
                                               
3
 If Bangladesh manages to transition to the “developing countries” group before 2016, this transition 
deadline will no longer hold. 
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Bangladesh to amend its national IP regime to conform to the TRIPS Agreement. The EU-
Bangladesh Commission is currently negotiating the U.S-Bangladesh Bilateral Investment 
Treaty and Article 1(c) of the agreement defines investment to include intellectual 
property protection.4 Bangladesh’s Parliament is expected to amend the country’s 
trademark, patent, and copyright legislations, following a lengthy inter-agency approval 
and clearance process, in order to make the country’s IP regime TRIPS-compliant. 
As part of these obligations, the Law Commission of Bangladesh has formulated a new 
Trade Marks Law that makes Bangladesh TRIPS-compliant, in consultation with the 
WIPO, expected to be placed before the Advisory Committee of the Cabinet for approval 
in May 2007.5 Similarly, new legislations for Patents and Designs (provisionally called the 
Patent Law 2007, and the Designs Law, 2007) have been formulated by the Ministry of 
Industries, which are presently with the Ministry of Law and Parliamentary Affairs for 
legal vetting and are expected to be enacted next year.6 The Draft Patent Law of 2007 
grants an exemption to the pharmaceutical sector, and provides that “It shall come into 
force at once except the provisions relating to examination, sealing, grant and post-grant 
matters of the patents relating to pharmaceutical and agricultural chemical products, but 
excluding the grant of exclusive marketing rights therefore and mailbox filings which shall 
come into force on and from the first day of January, 2016” (Section 1). Until these laws 
come into force in Bangladesh, its present policy framework for intellectual property 
protection consists of the Patents and Designs Act of 1911, the Trade Marks Act of 1940, 
the Copy Right Act of 2000 and the Merchandise Marks Act of 1889. 
3.2.1. Present patent regime 
The present patent protection regime comprises the Patents and Designs Act of 1911 (last 
amended in 2003) and the Patent and Design Rules of 1933. The Act deems patents to be 
valid for a total of sixteen years (Section 14), calculated from the date of application 
(Section 7), and allows a further extension of ten years (Section 15(a)(1)).7 Section 8 
                                               
4
 Article 1 (c) of the treaty specifies that intellectual property rights includes rights with respect to 
copyrights, and related patents, trade marks, trade names, industrial designs, trade secrets and know-how, 
and good will. 
5
 Pers. Comm., Mesbah Uddin, Registrar, Department of Patents, Designs and Trademarks, 17 April 2007. 
6
 Pers. Comm., Mesbah Uddin, Registrar, Department of Patents, Designs and Trademarks, 17 April 2007. 
7
 Section 7 reads: “After the acceptance of an application and until the date of sealing a patent in respect 
thereof, or the expiration of the time for sealing, the applicant shall have the like privileges and rights as if a 
patent for the invention has been sealed on the date of the acceptance of the application.” Section 15(a)(1) on 
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contains provisions for opposition to grant of patent (within four months from the date of 
advertisement of acceptance of application). The law grants both process and product 
patents on pharmaceuticals.8 Patent statistics between 2000 and 2005 are contained in 
Table 5 below. According to the local patent office, of the 182 patents granted in 2005, 
over 50 per cent are pharmaceutical patents.9  
Table 5: Patents Granted in Bangladesh between 2001 and 2006 
Applications Filed Applications Accepted Year 
Local Foreign Total Local Foreign Total 
2001 56 239 295 21 185 206 
2002 43 246 289 24 233 257 
2003 58 260 318 16 206 222 
2004 48 268 316 28 202 230 
2005 50 294 344 21 161 182 
2006 23 287 310 16 146 162 
           Source: Department of Patents, Design and Trademarks, Bangladesh 
3.2.2. Export of ARVs and other patented drugs using TRIPS flexibilities 
The present patent regime in Bangladesh does not contain a provision that enables firms to 
export to other LDCs as per the TRIPS flexibilities. Section 22 of the Patents and Designs 
Act of 1911 deals with the grant of compulsory licenses and revocation of patents. 
According to this section, any person can present a petition to the government of 
Bangladesh that the demand for a patented article is not being met, but this is presumably 
for the local market only. Under such circumstances, the government or the high court 
division may order the patentee to grant licenses on terms they see fit. A revocation can 
also be made within grant of four years of the patent, in case the patentee fails to give 
adequate reasons for his default (Section 22 (4)). Thus, contrary to the view projected in 
some recent reviews on this topic (see GTZ, 2007; Bumpas, 2007), in the absence of a law 
that either contains TRIPS flexibilities for export of generic versions of patented drugs to 
other least developed countries that have TRIPS-compliant regimes or denies the 
enforcement of patents on pharmaceutical exports, there does not seem to be a legitimate 
                                                                                                                                             
‘Patents of Addition’ provides that “Where a patent for an invention has been applied for or granted, and the 
applicant or the patentee, as the case may be, applies for a further patent in respect of any improvement in or 
modification of the invention, he may in his application for the further patent request that the term limited in 
the original patent or so much of that as is unexpired, and if he does so, a patent (herein after, referred to as a 
patent of addition) may be granted for such term as aforesaid.” 
8
 Pers. Comm, Mesbah Uddin, Registrar; Farhad Hossain Khan, Assistant Registrar (Patents) and Azim 
Uddin, Assistant Registrar (Copyrights), Department of Patents, Designs and Trademarks, 17 April 2007. 
9
 Pers. Comm, Mesbah Uddin, Registrar; Farhad Hossain Khan, Assistant Registrar (Patents), 17 April 2007. 
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legal basis for firms to indulge in exports, even if they can produce the drugs locally. The 
local patent regime especially needs to focus not just on the express permission to export 
but on simplifying the procedures for application of compulsory licenses (which are 
presently extremely cumbersome) and also on including export as a ground for issuing a 
compulsory license. The enactment of a law that states ‘exports’ as a ground for issuing a 
compulsory license is very important, in the absence of which if a drug for the cure of 
HIV/AIDS is patented in Bangladesh under the present patent regime, local companies 
will not be able to argue for the issue of a compulsory license purely on the basis of the 
local market since there is no local HIV/AIDS crisis in the country. 
Table 6: Exports of patented drugs by Bangladesh’s pharmaceutical firms 
Exports of patented drugs by Bangladesh’s firms: Key legal pre-requisites 
Local firms in Bangladesh could export to other least developed countries generic versions of drugs 
patented elsewhere, if both Bangladesh and the importing countries do not provide pharmaceutical 
patents. Bangladesh’s own patent regime presently recognizes product and patent protection for 
pharmaceuticals. It is not clear if many of the important drugs that are essential to ensure access to 
medicines are already patented within Bangladesh. 
Furthermore, most African and non-African least developed countries have granted product patent 
protection to pharmaceuticals as required by the TRIPS Agreement, despite the 2016 extension 
(UNCTAD, 2007). Therefore exporting patented drugs to these LDCs requires: (a) a national 
legislation in the importing country that incorporates the TRIPS flexibilities, including the 30 August 
2003 decision; and, (b) a legislation in Bangladesh that allows the local firms to export to other 
TRIPS-compliant countries through a compulsory license (ibid.). 
Under the Doha Declaration on TRIPS and Public Health and 30 August 2003 Decision on the 
implementation of paragraph 6 of the Doha Declaration, least developed countries without adequate 
manufacturing capabilities can obtain supplies from another country with manufacturing capabilities, 
such as Bangladesh, under a compulsory license. This compulsory license would be issued to the local 
firm in Bangladesh solely for purposes of supplying the patented product to the least developed 
country in need of the product, but lacking the local manufacturing capabilities to produce it.  
Under the present patent regime in Bangladesh, if international firms choose to patent their drugs in 
the country, it would be illegal for the local firms to engage in their production. Section 84 (10) of the 
Draft Patent Act of 2007 incorporates the TRIPS flexibilities in this regard, which is a legal 
prerequisite for the local firms to produce and sell generic versions of patented drugs to other least 
developed countries which do not have pharmaceutical manufacturing capabilities. Thus, enactment of 
the draft Patent Act is a key legal pre-requisite. 
Source: Author. 
The draft Patent Act of 2007 contains all the exceptions for pharmaceutical products in 
accordance with the TRIPS Agreement and the Doha Declaration on the TRIPS 
Agreement and Public Health, but may not be enacted soon due to the political situation in 
the country. Section 84, clause 10, of the Draft Patent Act of 2007 contains provision for 
grant of compulsory licenses for the “…manufacture and export of patented 
pharmaceutical products to any country having insufficient or no manufacturing capacity 
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in the pharmaceutical sector for the concerned product to address public health problems, 
provided compulsory license has been granted by such country.” This compulsory license 
is solely meant to be for the manufacture of that particular pharmaceutical product for 
which the license is obtained, and to the country that grants the license, under terms and 
conditions specified by the importing country and the registrar of the Patents Office of 
Bangladesh (Sec. 84, clause 11). For purposes of this section, “Pharmaceutical products” 
are defined as any patented product, or product manufactured through a patented process, 
of the pharmaceutical sector needed to address public health problems and shall be 
inclusive of ingredients necessary for their manufacture and diagnostic kits required for 
their use.” Thus, the enactment of the Draft Patent Act is an imperative for the export of 
patented drugs by Bangladeshi firms. 
4. THE PHARMACEUTICAL SECTOR IN BANGLADESH 
Bangladesh exports a wide range of pharmaceutical products (therapeutic class and dosage 
forms) to 67 countries.10 The Drug Control Ordinance of 1982 placed a ceiling on selling 
imported drugs in the local market promoted self-reliance in its pharmaceutical sector, 
prior to which the local manufacturing catered to only 20 per cent of the total needs. Local 
exports have risen from USD 0.04 million in 1985 to USD 27.54 million in 2006 (Export 
Promotion Bureau). As opposed to relying on foreign companies for 75 per cent of their 
drug supply prior to the Ordinance, local firms now cater to 82 per cent of the markets, 
whereas subsidiaries of MNCs supply 13 per cent of the market and 5 per cent of the drugs 
are imported (Ibid.). Square Pharmaceuticals is the largest firm in the market for many 
years now, and is followed closely by Beximco, Incepta, ACME and Eskayef (IMS, 2006). 
Other firms in the top ten bracket include Aristopharma, General, Healthcare Pharma, 
Novartis and Drug International (Ibid.).  
                                               
10
 Pers. Comm., Dr. Habibur Rahman, Director, Drugs Administration, 11 April 2007. 
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4.1. Nature of Innovation in the Local Pharmaceutical Sector 
Pharmaceutical firms in Bangladesh are mainly 
engaged in formulation of APIs requiring 
manufacturing skills only, and are presently 
struggling to build capacity in the more 
knowledge-intensive processes of reverse 
engineering active pharmaceutical ingredients 
(APIs). Formulation activities are carried out in 
most indigenous firms and a small percentage of 
subsidiaries of international firms that operate in 
the market, and both groups were captured by the 
survey. 
Approximately 450 generic drugs, in 5,300 registered brands having 8,300 different 
presentations of dosage forms and strengths are manufactured by 237 registered 
companies (including 5 multinationals) in the sector. The local companies produce a wide 
range of products that include antiulcerants, flouroquinolones, antirheumatic non-steroid 
drugs, non-narcotic analgesics, antihistamines, and oral antidiabetic drugs. The survey 
shows that many of the bigger firms are now venturing into the production of anti-cancer 
drugs, anti retroviral drugs for the treatment of HIV/AIDS11 and anti Bird Flu drugs. 
4.2. Firm Size and Market Concentration 
The companies include specialized multinational companies, local large companies with 
international links and smaller local companies. Out of the 237 registered companies, only 
around 150 are estimated to be in a functional state.12 The Bangladesh Association of 
Pharmaceutical industries (BAPI) is the main professional association for the sector, and 
has 150 member companies that lobby the government for policy changes, among other 
activities. The local market is extremely concentrated with the top ten firms cater to about 
70 per cent of the market and only two companies, Beximco and Square hold 25 per cent 
                                               
11
 Square Pharmaceuticals is currently engaged in manufacturing eight drugs that are part of several ARV 
combinations that are expected to be available in the market later this year. Pers. Comm. Parvez Hashim, 
Executive Director Operations, Muhammadul Haque, Director Marketing and Md. Nawabur Rahman, 
Assistant General Manager, Square Pharmaceuticals, 9 April 2007. 
12
 Pers. Comm.., Dr. Habibur Rahman, Director, Drugs Administration, 11 April 2007. 
Apart from Beximco, Square Pharmaceuticals is 
currently engaged in the manufacture of several drugs 
that are part of ARV combinations and are expected to 
the available in the market later this year. These include: 
Adiva (Efavirenz), Hivarif (Lamivudine), Avudin 
(Lamivudine and Zidovudine), Tivizid (Abacavir, 
Lamivudine and Zidovudine) and Nelvir (Nelfinavir). 
Indian firms like Aurobindo (which has four drugs 
approved for PEPFAR supply – Nevirapine, 
Lamivudine, Efavirenz and Stavudine), Cipla, Hetero 
and Dr. Reddy’s, all supply APIs to Square 
Pharmaceuticals.* 
 
*Pers. Comm. Parvez Hashim, Executive Director 
Operations, Muhammadul Haque, Director Marketing 
and Md. Nawabur Rahman, Assistant General Manager, 
Square Pharmaceuticals, 9 April 2007.  
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of the entire market (Chowdhury et al, 2006). This also points out to the extreme 
disparities in firm sizes and capabilities, as far as innovation as well as marketing 
capabilities is concerned. 
5. INNOVATIVE CAPABILITIES OF FIRMS IN BANGLADESH’S 
PHARMACEUTICAL SECTOR 
Local pharmaceutical firms in Bangladesh are struggling to master the process of 
manufacturing APIs from scratch. The few firms in Bangladesh that are presently 
producing APIs locally are only able to perform the last few steps in the process with help 
from technologies bought from Indian firms.13 Square Pharmaceuticals, which is the 
largest local firm, lists the following thirteen APIs as its mainstay: Amoxycillin Trihydrate 
(both Compacted and Micronised) BP/USP, Amoxycillin Trihydrate (Micronised) 
BP/USP, Cloxacillin Sodium (Compacted and Micronised), Cloxacillin Sodium 
(Micronised) BP/USP, Paracetamol BP/USP, Diclofenac Sodium BP/USP, Diclofenac Di 
Ethyl Amine BP, Diclofenac Potassium BP, Diclofenac INN (Free Acid), Flucloxacillin 
Sodium (Compacted and Micronised) BP, Cephalexin Monohydrate (Compacted and 
Micronised) BP/USP.14 Beximco, another major local pharmaceutical company, has two 
top-selling brands - Neoceptin R (Ranitidine) and Napa (Paracetamol) in the local 
market.15 
The lack of reverse engineering capabilities amongst the pharmaceutical firms was 
confirmed through observed R&D investments over 2000-2005 as captured by the survey. 
The survey shows that there was not much difference in the amounts invested in R&D 
between the pharmaceutical firms, and those in agro-processing and textiles and garments 
(about 1 per cent). At a first glance, this seems to be a surprising result, since it implies 
that R&D and innovations are not (statistically and significantly) correlated with one 
another in the pharmaceutical sector in Bangladesh, although generally speaking the 
pharmaceutical sector is very technological intensive and far more innovative in terms of 
new product/process innovations when compared to low technology sectors such as 
                                               
13
 Pers. Comm., Parvez Hashim, Executive Director Operations, Muhammadul Haque, Director Marketing 
and Md. Nawabur Rahman, Assistant General Manager, Square Pharmaceuticals, 9 April 2007; Amanullah 
Chowdhury, Executive Vice President and Habibur Rahman, Vice-President and Director, Rangs Pharma, 16 
April 2007. 
14
 Square Annual Reports, 2006-2007. 
15
 Beximco Pharmaceuticals could not be interviewed personally for the study due to political circumstances 
in the country and the firm’s management at the time of the survey. However, the company participated in 
the survey. 
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textiles and agro-processing (Gehl Sampath, 2007). But in the context of LDCs, it 
confirms the extensive relationship between firms and the knowledge systems they are 
entrenched in. The difficult state of the domestic knowledge system in the country (see 
UNCTAD 2006, Chapter 6), forces firms operating in what is normally a high-technology 
sector to focus on manufacturing and excludes the more knowledge-intensive activities 
from their reach. 
This lack of capacity to locally produce APIs reduces the competitiveness of the firms 
enormously, since between 30 and 50 per cent of the production price of the drugs is taken 
over by the expenses of securing APIs from external sources (Bumpas, 2007). The top 
local firms (around six in total) are trying to secure skills and scientific infrastructure in 
order to venture into API production and reverse engineering.16 However, they are stifled 
by lack of adequate scientific and physical infrastructure. Lacking scientific infrastructure 
includes missing human resources as well as the incapacity of domestic research and 
development institutes, (RDIs) and universities in assisting the firms in developing these 
chemical synthesis skills due to under-funding of research, disillusion of scientists and 
researchers and lack of a cogent focus amongst core university faculties that do work on 
medical sciences. This disarticulation between various components of the domestic 
knowledge systems illustrates a prevailing phenomenon that prevents effective learning 
and absorption by the enterprise sector in most LDCs. Most exporting firms in the survey 
pointed out cheap labour costs as their main advantage in the international markets, but 
even the biggest firms like Square Pharmaceuticals were skeptical about whether they 
could capture markets in other African and Asian countries on the basis of just cheap 
labour when they did not possess the economies of scale and reverse engineering skills on 
par with their Indian counterparts.17 
Apart from this, a range of factors, including lack of common industry infrastructure, lack 
of capabilities to conduct bioequivalence tests in the country, and the lack of 
biotechnological capabilities to branch out into emerging options such as biogenerics, all 
curb their innovative capacity. The top Bangladesh firms are keen on diversifying exports 
                                               
16
 Pers. Comm., Joint meeting with the members of the Bangladeshi Association of Pharmaceutical 
Industries (BAPI), 11 April 2007. 
17
 Pers. Comm., Parvez Hashim, Executive Director Operations, Muhammadul Haque, Director Marketing 
and Md. Nawabur Rahman, Assistant General Manager, Square Pharmaceuticals, 9 April 2007; Amanullah 
Chowdhury, Executive Vice President and Habibur Rahman, Vice-President and Director, Rangs Pharma, 16 
April 2007. 
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between regulated and unregulated markets, since sales from regulated markets can be 
huge once the initial hurdles of market entry are countered. Square Pharmaceuticals, for 
example, has invested huge sums in setting up production facilities that meet exporting 
requirements to the UK (and planning to expand to the USA too) just outside of Dhaka. 
The absence of infrastructure support to conduct bioequivalence tests and the lack of 
biotechnological capabilities pose big barriers to such firms seeking to branch out into 
emerging options such as bio generics or focus on exporting to regulated markets. All 
these factors are their impact on innovative capacity are discussed in detail here. 
5.1. Disarticulation within the Local Knowledge System for Pharmaceutical Research 
The gradual transition from manufacture to knowledge-intensive reverse engineering skills 
in the pharmaceutical sector assumed the availability of human skills and scientific and 
physical infrastructure. For developing countries seeking to build capacity, this is a 
significant hurdle to surmount. As elaborated already in section 3 of the paper, Bangladesh 
has very weak knowledge infrastructure, in terms of secondary and tertiary enrolments, 
R&D investments and scientists per million of the population. Specifically in the context 
of pharmaceutical research, the survey reveals that the disarticulation between university 
and public sector research and the enterprise sector is very strong, and one of the largest 
impediments to building API skills. 
University education: University education of relevance to the pharmaceutical and health 
sector in Bangladesh can mainly be divided into three fields: medical education, nutrition 
and biochemistry and pharmacy education. In the public sector, there are 13 governmental 
medical colleges, two institutes for health technology, six post-graduate institutes, three 
specialized institutes and five medical assistant training colleges in Bangladesh, all meant 
to impart training of relevance to both the pharmaceutical and health sector (Osman, 
2004). Among the university faculties, Dhaka University is highly reputed with very 
established departments that deal with pharmaceutical sciences followed by others such as 
Jehangir Nagar University. Apart from these public universities, Bangladesh has recently 
seen the mushrooming of several private universities, like BRAC University, North-South 
University, Stanford University, among others. 
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R&D institutions in biomedical sector: There are a number of R&D institutions under the 
Ministry of Health and Family Welfare. These institutions conduct study and research in 
specific areas. Some of these are: Institute of Public Health; Bangladesh Medical Research 
Council; Bangladesh National Research Council; Institute of Epidemiology Disease 
Control and Research; International Centre for Diarrhoeal Disease Research, Bangladesh 
(ICDDR,B); National Institute of Cancer Research and Hospital; National Institute of 
Cardiovascular Disease; National Institute of Ophthalmology and Hospital; National 
Institute of Population Research; National Institute of Preventive and Social Medicine; 
and Rehabilitation Institute and Hospital for the Disabled. 
Despite the presence of these institutions, very low levels of collaboration between firms 
and public sector institutions involved in R&D, teaching and delivery of health services is 
observed in Bangladesh. Table 7 shows the observable patterns of product and process 
innovations in the Bangladesh’s pharmaceutical sector based on survey data. These 
patterns of innovation amongst firms and public sector actors are quite different from what 
one would expect. More specifically, almost no universities and public research institutes 
and no hospitals are involved in new product development (4.65% and 2% respectively) 
and new process development activities (6.98% and 2% respectively). Furthermore, a very 
small percentage of universities and public research institutes (2.33%) and none of the 
hospitals are involved in both product and process development. As for the pharmaceutical 
firms, a majority of them (95.56%) are involved in new product development. While the 
percentage of firms involved in new process development is much higher than 
universities/ public research institutes and hospitals, it is much lower (31.11%) than that of 
firms involved in new product development. When the sector is taken as a whole, 33.33 
per cent of all actors are involved in new product development and 13.04 per cent are 
involved in new process development and 10.87 per cent are involved in both. 
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Table 7: Observable patterns of product and process innovations 
New 
product 
development 
New process development 
 Universities/ PRIs Firms Hospitals All 
 No Yes Total No Yes Total No Yes Total No Yes Total 
No 39 2 41 2 0 2 48 1 49 89 3 92 
% 90.70 4.65 95.35 4.44 0 4.44 96 2 98 64.49 2.17 66.67 
Yes 1 1 2 29 14 43 1 0 1 31 15 46 
% 2.33 2.33 4.65 64.44 31.11 95.56 2 0 2 22.46 10.87 33.33 
Total 40 9 43 31 14 45 49 1 50 120 18 138 
% 93.02 6.98 100 68.89 31.11 100 98 2 100 86.96 13.04 100 
 Source: Author’s survey, 2006-2007 
 
Table 8: Collaboration matrix between various actors in the domestic knowledge 
system 
Collaboration intensity with Universities/ 
PRIs 
Firms Hospitals 
Public research institutes 2.348 1.067 1.44 
Industrial Associations - 2.535 1.10 
Universities 3.027 1.758 1.700 
Private Laboratories 2.304 3.796 1.600 
Hospitals and med. practitioners 2.790 4.066 2.640 
Other firms 1.835 1.935 - 
NGOs 1.837 1.510 - 
Government Agencies 2.736 2.555 - 
         Source: Author’s survey, 2006-2007 
Table 8 shows collaboration intensities of universities and PRIs, firms and hospitals with 
all other counterparts in the pharmaceutical innovation system, namely, industrial 
associations, medical practitioners, NGOs, governmental agencies, among others. The 
figures in the table present the mean of rankings between 1 (least important) and 5 (most 
important). Thus, any ranking above 2.5 would represent moderate collaborative efforts 
between any two sets of actors. The rankings in the table reveal again that there is very 
little collaboration between different actors in the system as far as innovation is concerned. 
Firms tend to collaborate strongly with private laboratories and medical practitioners (for 
sale of their products, see discussion in section 5.3), and moderately with industrial 
associations and governmental agencies (for lobbying). Similarly, universities tend to 
collaborate strongly with other universities and moderately with medical practitioners and 
governmental agencies. 
This result is quite the inverse of what is observed in most countries with thriving 
pharmaceutical sectors, where public sector institutions play an important role in the 
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acquisition, use and application of knowledge to newer products. Thus normally, one 
would expect to see strong collaborations between public sector institutions (who conduct 
primary and applied research of relevance) and firms (for product development), as well as 
interactions with other actors such as hospitals (for supply) and governmental agencies 
(for infrastructure support). 
In Bangladesh, there are several reasons for the disarticulation between public sector 
research and pharmaceutical product development as well as the skewed patterns of 
collaboration. To begin with, university and research in PRIs is grossly under-funded. The 
government allots only 12 crore takas (equivalent to USD 1.75 million) for public sector 
research for the entire country which are to be shared amongst universities, PRIs, NGOs 
and all other public sector institutions.18 The status of research even under the premier 
university departments and PRIs is not sufficiently supportive towards developing local 
API skills.19 There is a lack of university courses that are tailor-made to produce 
chemistry-based skills of the kind required to reverse engineer in the pharmaceutical 
sector. Additionally, lack of funding and focus are major handicaps for all the universities. 
The laboratory facilities in disciplines such as pharmaceutical sciences and biotechnology 
research, which are being taught in several public and private universities, are also not 
enough to create human skills that can be directly deployed by the industry.20 Whereas 
several universities are only now creating courses for both these disciplines (which implies 
that it will take several years for competent streams of manpower to develop), the 
curriculum and quality of the courses also need to be assessed. There are no official 
rankings available of the quality of academic courses in the universities within the 
country, and the procedures for accreditation of courses for newer universities need 
monitoring.21 Most firms surveyed complained that they had to train graduates in aspects 
                                               
18
 Joint meeting, Department of Clinical Pharmacology, Department of Pharmaceutical Chemistry and 
Department of Pharmaceutical technology, Dhaka University, 10 April 2007. 
19
 Pers. Comm., Parvez Hashim, Executive Director Operations, Muhammadul Haque, Director Marketing 
and Md. Nawabur Rahman, Assistant General Manager, Square Pharmaceuticals, 9 April 2007; Amanullah 
Chowdhury, Executive Vice President and Habibur Rahman, Vice-President and Director, Rangs Pharma, 16 
April 2007. 
20
 Joint meeting, Department of Clinical Pharmacology, Department of Pharmaceutical Chemistry and 
Department of Pharmaceutical technology, Dhaka University, 10 April 2007; Joint Meeting, Department of 
Pharmacy and Department of Microbiology, Jehangir Nagar University, 12 April 2007. The Biotechnology 
Policy of 2005 has created five national executive committees on biotechnology, and development of 
pharmaceutical biotechnology falls under the National technical committee on medical biotechnology. 
21
 As mentioned earlier, on an unofficial basis, Dhaka University is rated to be the best on grounds of its 
historical importance as well as the fact that it receives maximum support from governmental initiatives 
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of clinical pharmacy for a year after they are employed (field interviews) since university 
graduates are not geared for clinical work in firms. 22 
5.2. Lack of GMP Standards and Bioequivalence Facilities 
Presently, there is no law prescribing GMP standards for the pharmaceutical drugs that are 
sold in the local market. Around six of the big firms are in the process of receiving GMP 
certification, and Square Pharmaceuticals has received regulatory approval from the 
British authorities earlier this year.23 The New Drug Policy of 2005 states in its objectives 
that the sector requires the enactment of good manufacturing standards in order to promote 
safety and efficacy of drugs for the local market. There is a need to enact rules that 
promote this objective in order to boost the export of pharmaceutical products, as well as 
to ensure safe and efficacious access to medicines in the local market.24 
Lack of facilities within the country to conduct bioequivalence tests means that even the 
biggest firms like Square Pharmaceuticals have to outsource their products to 
bioequivalence laboratories in countries like Malaysia (field interviews). In addition, the 
country does not have any good laboratory facilities for biotechnology-based work, which 
is another big hindrance to the bigger firms seeking to diversify their exports to the 
regulated and semi-regulated markets worldwide.  
                                                                                                                                             
(field interviews) but how Dhaka university as well as other universities fare in relative and absolute terms 
as far as the quality of education in pharmaceutical sciences is concerned is unclear. 
22
 Refer to Annex 5 for a ‘Policy Support Vision’ Statement drafted by the professors of the various faculties 
at the Dhaka University for policy action in this regard. 
23
 According to the office of the Drug Directorate, around 8 drug firms have WHO-pre-qualified products, 
and another 6 are presently in the process of acquiring WHO prequalification but this could not be 
corroborated by the survey. Pers. Comm., Dr. Habibur Rahman, Director, Drugs Administration, 11 April 
2007.  This may be due to confusion between WHO prequalification for products and certificates for 
pharmaceutical products, which is also a WHO certification scheme but national authorities issue the 
certificates for firms who comply with the form and content prescribed by the WHO.  
24
 Several factors prevent cheap access to medicines in the local market within Bangladesh, especially in the 
public sector health institutions. For a detailed analysis see Gehl Sampath (2007).  
 27 
5.3. Nexus between the Pharmaceutical and Health Sector and Misallocation of Human 
Skills 
There is a relatively large mismatch amongst the qualifications of personnel as well as 
facilities available to enable them to perform in the various organizations and several of 
these accrue from the (dis)incentives to various actors in the local pharmaceutical sector. 
Aspects of the health sector in the country, especially those related to drug procurement 
and sales, interact perversely with pharmaceutical production incentives and contribute to 
low competitiveness of the Bangladeshi firms. Since local firms mainly engage in 
formulation activities, quality control and quality assurance personnel are in large demand. 
The country produces a large number of qualified pharmacists most of whom are absorbed 
by the pharmaceutical firms, and employed for quality assurance and quality control 
activities for the manufacture of drugs. As a result, most pharmacies in the country are run 
by pharmacy owners, or personnel who have very little professional training (field 
interviews).  
Furthermore, the internal market is characterized by branded competition: each product 
essentially a generic, competing on the basis of brand names. In the absence of control 
mechanisms that check for GMP standards and bioequivalence of drugs marketed locally, 
the drug distribution system is organized solely around pharmacies (run by unqualified or 
inadequately qualified personnel) and doctors. This offers ample scope for the sale of low 
quality drugs at high prices, with firms relying solely on extensive distribution systems 
that promote their brand name products through medical practitioners, often in unethical 
ways. This is the reason for the skewed patterns of collaboration observed in table 8: firms 
tend to collaborate very highly with medical practitioners for distribution of their products. 
Also, drug supplies through both institutional and private pharmacies proceed through 
suppliers and retailers in a market that is not well regulated, and offers ample scope for 
price-fixing and other anti-competitive practices (World Bank, 2007a). 
Table 9 below shows, for each group (firms, universities and PRIs and hospitals) and for 
the whole sector, descriptive statistics of the key actors that are expected to carry out 
innovation empirically. It lends strength to the analysis on incentives of actors and the 
performance of the local innovation system. The table shows that employment in 2005 is 
much larger on average in pharmaceutical firms than in universities/ PRIs and hospitals, 
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which confirms again the dismal state of research infrastructure as well as supply-side 
institutions to provide medical services in the country. Similarly, pharmaceutical firms are 
much older on average than university departments/ PRIs and hospitals, the last two 
groups being equally old on average. The division of skilled labour amongst these various 
organizations (universities, PRIs, firms and hospitals) as captured by the survey and 
presented in table 9 is very important in explaining several of the innovative patterns in 
the sector presently and call for a closer look. The largest percentage of R&D performers 
in any year of the period 2001-2005 is found in pharmaceutical firms (82%) and the 
smallest one is found in hospitals (10%). The pharmaceutical firms, who are the largest 
R&D performers in the system, have the largest share of personnel with bachelors’ 
degrees. This again is an indicator of the kinds of innovation the firms are engaged in. The 
R&D personnel in 2005 are the largest in universities/ PRIs (with the largest share of staff 
with PhD degrees) which have hardly any funds to support their activities.  
Table 9: Descriptive statistics: Key actors of innovation 
Mean (Std. Dev.) Mean (Std. Dev.) Mean (Std. Dev.) Mean (Std. Dev.) Variable 
Universities/ PRIs Firms Hospitals All 
Employment in 
2005 (FTEs) 
116.837 (324.278) 922.867 (694.716) 181.320 (206.148) 403.036 (578.664) 
Age (in years) 10.884 (11.280) 21.444 (15.56) 10.060 (10.296) 14.029 (13.476) 
% of staff with 
PhD 
0.146 (0.200) 0.001 (0.001) 0.032 (0.042) 0.057 (0.129) 
% of staff with 
MSc 
0.243 (0.240) 0.348 (0.180) 0.107 (0.078) 0.228 (0.201) 
% of staff with 
BSc 
0.100 (0.175) 0.298 (0.115) 0.108 (0.090) 0.168 (0.158) 
Non-R&D 
performers 2001-
05 
0.535 - 0.178 - 0.900 - 0.551 - 
R&D personnel 
in 2001-2005 
0.091 (0.184) 0.008 (0.008) 0.001 (0.006) 0.031 (0.110) 
# of observations 43 45 50 138 
Source: Author’s survey, 2006-2007 
The survey also found that there is an overlap of competencies between medical practice, 
teaching and research in the sector, due to the lack of relevant manpower to conduct these 
activities, as well as regulations that prevent professionals from getting employed in 
conflicting activities. Practicing doctors also teach at university departments (with very 
little time or effort on improving course curricula) and also are involved with several 
large/ medium scale firms in their formulations activities as research consultants. This is 
once again confirmed by the collaboration patterns reported in Table 8: university 
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researchers, for example, collaborate intensely only with other universities and medical 
practitioners. This creates inherent conflicts of interest, and is one of the biggest problems 
in the nexus of the health and pharmaceutical sector in the country. 
5.4. Lack of a coherent policy framework to promote pharmaceutical innovation 
The problems of disarticulation between public sector research and product development, 
as well as misallocation of skills owing to perverse overlaps between the pharmaceutical 
and health sectors can all be credited to the lack of a coherent policy regime for the 
pharmaceutical sector. The Drug Control Ordinance of 1982 was in several ways, very 
similar to India’s policy initiative of a similar kind that triggered self-reliance in its 
pharmaceutical sector, but this policy has not been supported by complementary industrial 
policy measures to support the sector. Thus, although it promoted the growth of the sector, 
its present deficiencies can be traced back to the absence of a consistent, strategic policy 
framework that could steer it into a profitable and competitive trajectory.  Table 10 below 
contains a comparison of the similarities and differences between India’s and 
Bangladesh’s policy support regime for the growth of the pharmaceutical sector. A period 
of twenty years from the date of the introduction of the drug control regulations in both 
countries has been taken into account for this comparison.  
Table 10: Comparing Bangladesh and India’s Policy Regimes for Pharmaceutical 
Self-Sufficiency 
Bangladesh’s Policy Support Regime, 
1980s to 2000s 
India’s Policy Support Regime,  
1960s to 1980s 
Similarities 
 Drug Control Ordinance of 1982. 
 Setting up of public research institutes 
but lack of funding and vision.  
 Setting up of government-held 
companies for production. 
 Drug Price Control Order, 1970. 
 Setting up of government-held companies to 
boost the local production of drugs. 
 Setting up of extensive public research 
infrastructure for pharmaceutical research. 
Differences 
 No restrictions on pharmaceutical 
patents under the 1911 Act. 
 No comparable role of the government 
or public sector institutions to help firms 
to acquire reverse engineering skills. 
 No funding to public sector institutions; 
the BCSIR is almost defunct.25 
 Lack of vision and funding to reform 
 Restrictions on patenting of foreign 
pharmaceutical products under the Patents 
Act of 1971. 
 Proactive role in technology transfer related 
to reverse engineering to local firms, 
through public research institutes. 
 Extensive funding to public sector 
organizations to boost the capacity for 
                                               
25
 BCSIR stands for Bangladesh Centre for Scientific and Industrial Research. 
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the university education system. pharmaceutical research, especially CSIR, 
CDRI and IDMR.26 
 Introduction of university education to suit 
industry requirements (in chemistry and 
pharmaceutical sciences). 
 Other industrial policy measures, such as 
investment and ownership restrictions on 
multinational companies. 
    Source: Author’s surveys in India (2005) and Bangladesh (2006-2007). 
Apart from the few similarities, which helped to boost pharmaceutical manufacturing by 
local firms, the many differences are helpful to unravel the tale of missing competencies 
amongst Bangladesh’s pharmaceutical firms. The missing investments in public sector 
research, common industry infrastructure services, university education of relevance to 
building up reverse engineering skills as well as other industrial policy measures for 
technology transfer and investment all account for the difficulties faced by even the best 
firms in the country today.  
The pharmaceutical sector falls under the Ministry of Health and Family Welfare 
(MHFW) in Bangladesh, rather than the Ministry of Industry and Commerce (or Ministry 
of Science and Technology), which is generally the case in other countries. The sector has 
not been a leading sector in the most recent economic policies that seek to provide a 
variety of incentives for exports, although the government has enacted a New Drug Policy 
(2005) and a National Biotechnology Policy (2005), and is in the process of establishing 
an API park. The New Drug Policy (2005) contains provisions for technology transfer and 
some other incentives to MNCs to set up production facilities in the country both on a 
joint venture or independent basis, although it is not clear how this alone will help in the 
absence of other institutional incentives that promote knowledge intensive activities, such 
as human skills. The Directorate of Drug Administration is the key department in charge 
of the sector, and is supported by the Institute of Public Health, which has the mandate of 
supporting public health activities, quality control, and production of biomedicals, training 
and research. Both organizations are severely under-equipped and under-funded.27 One of 
the few services offered by the Directorate is the Bangladesh National Formulary, 
                                                                                                                                             
26
 The full forms are: Centre for Science and Industrial Research (CSIR), the Central Drug Research Institute 
(CDRI). 
27
 The Directorate of Drug Administration has only two laboratory facilities (in Dhaka and Chittagong) that 
can test about 3,500 samples of medicines a year. About 12,000 samples of different brands of medicines 
remain without test every year, although the regulations require that medicines are tested for quality and 
efficacy twice every year (Bumpas, 2007). 
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produced by the Directorate of Drugs Administration which contains a list of all drugs 
available in the country, with manufacturing details and price. 
Another peculiar problem with the Ministry of Health is that most government officials 
(except those that specifically occupy technical positions) that work for the ministry are 
medical doctors, who are forced to undertake tasks without necessary specialized skills. 
Doctors are assigned the task of planning and strategy, overseeing functions of the various 
departments, and even handle financial management responsibilities (field interviews). 
This seriously affects performance of the various organizations under the ministry. The 
survey found that within specialized institutions like the Institute of Public Health, 
production specialist occupations (for production of vaccines) are occupied by medical 
doctors. The civil service system is also based on regular two-year transfers for many of 
these positions. Those who invest the time to learn to perform the tasks that they are 
assigned to are transferred soon thereafter. Hence, most officials interviewed for the study 
thus expressed their frustration to invest in on-the-job learning (field interviews). 
Table 7 shows the patterns of the contribution of government policies and institutions to 
new product and new process development in universities and PRIs (model 1), firms 
(model 2) and both of them (in the pooled model 3).28 As the estimation results in the table 
reveal, the only factor that contributes to present innovation efforts in the pharmaceutical 
sector is skilled manpower and quality of local infrastructure services.29 All other 
governmental policies and institutions, such as innovation incentives by the government 
and local research in the PRIs and universities are very weak in promoting innovation 
activities in the sector. 
It also points out to the fact that even if the new Patent Act of 2007 that incorporates the 
Doha flexibilities for pharmaceutical patents in Bangladesh is enacted, strategic policy 
support is required to promote API and reverse engineering skills among the local firms, 
in order for them to effectively supply low cost generic versions of patented drugs to other 
LDCs. 
                                               
28
 The government policy and institution variables are not present in the hospital questionnaire.  
29
 A similar analysis of firms in the Indian pharmaceutical sector shows, in comparison, that skilled 
manpower, intellectual property protection, being a small entrepreneur and quality of local infrastructure 
were factors that played a role in new product/ process innovations. See Gehl Sampath (2006). 
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Table 11: Bivariate probit ML estimation results: Government policies and 
institutions 
Coefficient (Std. 
Err.) 
Coefficient (Std. 
Err.) 
Coefficient (Std. 
Err.) 
Variable 
Model 1 Model 2 Model 3 
New product development 
Govt. innovation incentives -1.209 (1.161) - - - - 
Scientific/skilled manpower 0.319 (0.464) 0.836** (0.307) 0.438 (0.562) 
Local univ. for R&D collaboration -0.131 (0.811) - - - - 
Local research inst. for R&D 
collaborations 
0.615 (1.220) - - - - 
Intellectual property protection 0.673 (0.911) -0.199 (0.617) 0.458 (1.109) 
Quality of local infrastru. services 0.788† (0.473) - - - - 
Availability of venture capital 0.673 (0.537) - - - - 
Govt.-firm technology transfer -2.020 (1.285) -0.725 (0.847) -0.239 (2.171) 
Staff transfer to local firms 0.610 (0.876) 0.680 (0.702) 1.313 (2.020) 
Pharmaceutical firms - - - - 3.687** (0.585) 
Intercept -0.384* (0.189) -0.323† (0.185) -2.256** (0.567) 
New process development 
Govt. innovation incentives -0.374 (1.265) - - - - 
Scientific/skilled manpower 0.303 (0.510) 1.061** (0.378) 0.870* (0.40) 
Local univ. for R&D collaboration 0.496 (0.940) - - - - 
Local research inst. for R&D 
collaborations 
-0.050 (1.361) - - - - 
Intellectual property protection 0.246 (0.981) -0.185 (0.710) -0.084 (0.74) 
Quality of local infrastru. services 1.110* (0.472) - - - - 
Availability of venture capital 0.504 (0.490) - - - - 
Govt-firm technology transfer -1.788 (1.375) -0.591 (0.899) -0.279 (0.95) 
Staff transfer to local firms 1.125 (0.750) 1.240† (0.652) 1.207† (0.67) 
Pharmaceutical firms - - - - 0.921* (0.41) 
Intercept -1.732** (0.317) 1.570** (0.288) -2.089** (0.43) 
Extra parameter 
ρ 0.524* (0.211) 0.583** (0.181) 0.618† (0.33) 
# of observations 88 
Log-likelihood -80.615 -86.479 -44.606 
LR test 304.0;73.112 )10( =−= valuepχ  000.0;75.832 )2( =−= valuepχ  
Significance levels:       † : 10%     * : 5%     ** : 1% 
Source: Author’s survey, 2007 
5.5. Intellectual property rights and potential limitations of technology transfer 
Closer scrutiny of the patents that have already been granted within the country shows that 
many of the patents are presently disregarded in the local market. A major explanation for 
this lies in the technological intensity of the local firms; their inability to reverse engineer 
offers the best form of protection for the foreign firms who sell their products in the local 
market. Given this, one is forced to question the motives of foreign firms to patent in the 
local market. One explanation is that the patent holder firms may wish to prevent 
competition from companies in other countries, such as India, who may still be keen on 
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generic versions of patented drugs that they can no longer sell in the Indian market for 
exports to Bangladesh. Another explanation is that foreign firms are resorting to patent 
within Bangladesh if only to avert the potential threat of competition from the local firms.  
It is highly unlikely that intellectual property protection will provide a direct incentive to 
innovate for local firms, since they are 
not into innovative activities at the 
frontier (see UNCTAD, 2007). An 
empirical analysis of the impact of 
intellectual property rights, both as a 
direct incentive for innovation as well as 
an indirect contributor to firm level 
technological upgrading through 
avenues such as technology licensing 
found very little support in the 
pharmaceutical sector in Bangladesh 
(Gehl Sampath, 2007). Technology 
licensing to local firms is marginal and not a contributor to innovative efforts presently in 
the local pharmaceutical sector in Bangladesh (Ibid.). Although the new Drug Policy has 
provisions for joint research and technology transfer between foreign firms and local 
firms, efficient technology transfer for the future, especially in the case of a knowledge-
intensive sector like pharmaceuticals, will hinge upon transfer of know-how (Arora, 1995, 
p. 41). Successful transfer of know-how, which is uncodified and costly to transfer will in 
turn depend on the technology absorption capacities of the recipient, and not just the 
willingness of the licensor (see box above). 
On the question of intellectual property rights protection and access to technologies, the 
Baby Zinc tablet that is now being produced and marketed by Acme Pharmaceuticals 
makes an interesting case. This product, originally developed by the Centre for Health and 
Population Research (ICDDR,B) is the only zinc product that meets pharmaceutical GMP 
standards as prescribed by the WHO, and is used for the prevention of diarrhoea in 
children. ICDDR, B tried to negotiate the production of the tablets with local 
pharmaceutical firms within Bangladesh but Nutricet, a French firm holds the formulation 
patent that was needed to produce the drug. This necessitated an agreement between 
Firms in Bangladesh require substantial help in 
developing local API skills, which could be promoted 
through south-south cooperation with the pharmaceutical 
sector in India. Amongst the firms that were surveyed, 
several large firms are in negotiation (or had failed to 
negotiate) transfer of skills and know-how from 
successful Indian firms. The government has allotted land 
and finances to building an API park that will also contain 
common effluent and waste management as well as water 
treatment facilities, and this may really help to speed up 
the process. Previous experience shows that technology 
transfer and collaboration helped to develop formulations 
capacity in the sector. Good examples are Square 
Pharmaceuticals which collaborated with Jansen and 
Vicsenco that received help from Pfizer. Even in these 
cases, the transfer of technology was accompanied by 
training of skilled manpower. But in the case of API 
skills, this may not be so easy, since the firms require 
access to know-how in addition to codified technology in 
order to build capacity.  
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Nutricet and the local firm in order to manufacture the tablets on a large scale. Square 
Pharmaceuticals, which first attempted to formulate the medicine for the local Bangladesh 
market on a commercial basis, withdrew its interest due to the high price it would have to 
pay to purchase the license for the formulation patent from the French company.30 
ICDDR, B intervened and negotiated the license with Nutricet on its own in 2005, and has 
now entered into an agreement with Healthcare Pharmaceuticals to produce the tablets.31 
This case although anecdotal, shows the problems inherent in negotiating commercial 
licenses for access to technologies. 
5.6. Narrow focus on the domestic market 
Most of the sales for even the largest firms accrue from the local market,32 but the size of 
the local market is quite small.33 The policy framework protects the local firms from 
imports of drugs that can be locally manufactured and the present marketing and sales 
incentives for firms (see next paragraph) are such that there seems to be very little 
incentive to enhance competitiveness (field interviews). The few firms that are in the 
process of expanding their range of activities to include API and reverse engineering skills 
are focusing on the export markets, and will need a lot of institutional support to achieve 
efficient results. 
6. Firm-Level Competitiveness in Bangladesh’s Pharmaceutical Sector and Access to 
Medicines  
The previous section paints a rather ambivalent picture of the innovative capabilities of the 
local pharmaceutical firms in Bangladesh. How competitive are the local firms, given all 
the constraints that they face, and how well-placed are they to move up to more 
knowledge-intensive activities required for self-sufficient production of generic drugs? 
This section seeks to answer some of these questions by comparing some indicators of 
firm-level competitiveness between India and Bangladesh. The data used for Indian firms 
was collected by the author during a firm-level survey of 103 firms in the Indian 
                                               
30
 Pers. Comm., Mohammadul haque, Director Marketing, Square Pharmaceuticals, 11 April 2007. According to Square, 
they were asked to pay a royalty of 200,000 Euros for the license by the French firm. 
31
 Pers. Comm., David Sack, Executive Director, ICDDR. B, 10 April 2007. 
32
 The first largest firm in the market, Square Pharmaceuticals is reported to be exporting only 3 per cent of 
its total production, and Beximco, another firm in the top five, exports only 2.7 per cent.  
33
 According to World Bank Statistics (2007), Bangladesh reported a population of 141.8 million in 2005.   
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pharmaceutical sector in 2005.34 The data used for Indian firms is from 2000-2004, 
whereas that for Bangladesh’s pharmaceutical firms is from 2001-2005.  
Apart from the evolution of the sector over time (policies and institutions as well as 
response of the main sector actors) which has been presented in the previous section, 
competitiveness of the firms is measured through indicators such as exports 
(manufacturing exports as a percentage of overall production of the firm), comparison 
among competences of different size classes (small, medium, large sized firms), observed 
rates of innovation, costs of production, including sources of machinery and production 
inputs (local and foreign) in this section.  
Figure 1 below shows the proportions of gross inputs sourced domestically in both 
countries, and figure 2 contains a further break up of inputs in terms of local production 
inputs and machinery. Pharmaceutical firms in Bangladesh mainly use process 
development technologies to manufacture generic formulations. The survey shows that the 
firms import between 75 to 100 per cent of their machinery and 50 to 100 per cent of all 
production inputs are imported from foreign sources. Active pharmaceutical ingredients 
are sourced from a range of countries including India, China, Italy, Spain, Germany, 
United Kingdom, France and the USA.35 As figure 1 shows, local firms reported to 
sourcing a maximum of 30 per cent of inputs locally, which stands in stark contrast to 
approximately 80 per cent domestic inputs amongst pharmaceutical firms in India.  
                                               
34
 The data was collected for a study commissioned by the WHO’s Commission on Intellectual Property 
Rights, Innovation and Health. The 203 firms that participated in the survey were within the top 150 firms in 
2005, based on annual turnover, R&D investments and exports.  
35
 Pers. Comm., Parvez Hashim, Executive Director Operations, Muhammadul Haque, Director Marketing 
and Md. Nawabur Rahman, Assistant General Manager, Square Pharmaceuticals, 9 April 2007; Amanullah 
Chowdhury, Executive Vice President and Habibur Rahman, Vice-President and Director, Rangs Pharma, 16 
April 2007.  
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Figure 1: Percentage of gross inputs sourced domestically in India 
and Bangladesh, 2000-2005 
 
Source: Author’s survey of Indian and Bangladesh pharmaceutical sectors, 2005-2007 
Figure 2: Sources of machinery and production inputs 
 
Source: Author’s survey of Indian and Bangladesh pharmaceutical sectors, 2005-2007 
Firms in both surveys were asked to report whether their innovations were (a) only new to 
the firm (b) new to the local market (c) new to the regional market, and (d) new to the 
global market. The response to this question, as shown in figure 3, captures the nature of 
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innovative activities at the firm level, and is also a clear indication of where a sector 
stands on the spectrum of innovative capacity for pharmaceutical innovation, as presented 
in the framework in section 2 of this study. Figure 3 below presents the survey response 
by firms in both countries. Whereas Indian firms reported to have innovations in all 
categories, with a sizeable amount of innovations reported to being new to the regional 
and global market, almost all the output of the pharmaceutical sector in Bangladesh is new 
to the firm or the local market only. 
Figure 3: Degree of novelty of innovations 
 
Source: Author’s survey of Indian and Bangladesh pharmaceutical sectors, 2005-2007  
Export intensity of local firms in Bangladesh is also quite low when compared to that of 
the Indian firms captured by both surveys. Even the biggest firms like Square and 
Beximco export 3 per cent and 2.7 per cent of their total output, whereas amongst the 
Indian firms, the exports can even account of over 70 per cent of total output (author’s 
survey, 2005). Similarly, other key indicators of firm-level competitiveness such as total 
employment (full time equivalents), R&D investments, number of R&D personnel 
employed within firms, level of education of R&D personnel, all show that Bangladeshi 
firms are lagging far behind their Indian counterparts. A comparison of mean R&D 
spending (as a percentage of sales) and mean R&D staff employed (as a percentage of 
total workforce) amongst pharmaceutical firms in both countries is presented in Figure 4.  
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Figure 4: R&D figures and personnel: Indian and Bangladesh pharmaceutical firms 
 
Source: Author’s survey of Indian and Bangladesh pharmaceutical sectors, 2005-2007 
6.1 The case of HIV/AIDS drugs: The competitive advantages 
Given these differences and the fact that economies of scale and reverse engineering skills 
are two critical factors in competitive supplies of drugs, what are the competitive 
advantages of Bangladesh’s firms and how can they be harnessed? 
India’s TRIPS-compliant patent regime that came into force in 2005 contains some 
interesting clauses that protect local generic firms while at the same time catering to 
access to medicines in the international market. The most notable amongst these are a 
provision that exclude the patenting of polymorphs/salts and esters of already existing 
molecules on grounds of lack of novelty (Section 3), and a provision that states that for all 
molecules that are patented between 1995 and 2005, Indian firms that have already 
invested in reverse engineering and manufacturing of the drugs can continue to do so, 
subject to the payment of a reasonable royalty to the patent holder firm. The law does not 
define “reasonable royalty”, and this is expected to be the cause of some litigation in the 
country (Grace, 2005). This means that Indian firms can still continue to produce several 
of 1st and 2nd line ARVs, despite the country’s TRIP-compliant regime. Table 12 contains 
a discussion on the drugs.  
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Table 12: ARVs and the Indian Patent Regime 
The fixed dose combination stavudine/lamivudine/nevirapine, comprises patents on the three 
individual drugs which were filed in 1987/1989 and 1990 and will expire in 2007/2009/2010 
respectively. Since all the three products were patented before 1 January 1995 (irrespective of the 
launch date of the products), each drug can be freely marketed without any arrangement with the 
patent holder company, irrespective of the expiry date of the patent. Indian generic companies are 
also free to develop and patent their own fixed dose combinations based on these three products. 
Combivir contains AZT (patented 1985) and lamivudine (patented 1987). Since both of these 
drugs are pre-1995, they are not individually eligible for patents in India. However, Combivir has 
a formulation (for the combination of the two in one tablet) patent with the priority date of 1997. 
Worldwide, no one can market this product until 2017 (2018 in the US). Indian drug firm, Cipla, 
which has been manufacturing Combivir for years already took GlaxoSmithkline to court in the 
UK on grounds of “lack of novelty” for its patent on Combivir (GB2235627), which Cipla claimed 
was a combination of its earlier two ARV products, AZT (patent expiry date 2005) ands 
Lamivudin (patent expiry date 2007). Cipla won the case in the UK in 2004. Within India, Cipla 
can challenge the validity of GSK’s patent, asserting that the formulation should not be patentable.  
The patent for Tenofovir has been issued in 1992, but the priority patent date for the ester/ salt on 
of the molecule, Tenofovir Disoproxil Fumerate, is 1997. Gilead filed a patent application in India, 
for which a pre-grant opposition was filed by MSF in 2006. Cipla launched ‘Tenvir’, its own brand 
of tenofovir disoproxil fumarate (TDF), in September 2005. Gilead came out with a statement in 
May 2006 stating that its patent application will not run counter to access to medicines goals and it 
is ready to grant voluntary licenses to all firms (within India and otherwise) for the manufacture of 
generic versions of the drug.  
Source: Grace (2005); Gehl Sampath (2005) 
Whether local firms in Bangladesh can compete with Indian firms already producing 
ARVs, by sourcing their APIs from them (see the box on Square’s API productions in 
section 4) is unclear. The question that needs to be resolved in this context is whether 
Bangladesh’s firms can compete with their Indian or other counterparts who have the 
advantage of sourcing their own APIs as well as demonstrate much higher technological 
sophistication, in addition to possessing the required economies of scale? The niche for 
firms in Bangladesh’s pharmaceutical firms seems to be to focus on post-2005 molecules 
where Indian firms will have much difficulty gaining foothold for reverse-engineering and 
manufacture due to TRIPS requirements. It remains to be seen, however, if the new data 
protection regime in India will improve the prospects for Bangladesh’s local firms. The 
main steps that should be taken to enable Bangladesh’s firms to attain competitiveness to 
become potential suppliers of such drugs (as well as many others) are listed out in the next 
section. 
7. CONCLUSIONS 
The pharmaceutical sector in Bangladesh has received a lot of attention in the context of 
access to medicines and the TRIPS Agreement in recent times. With India becoming 
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TRIPS-compliant in 2005, the sector in Bangladesh could potentially fill the vacuum 
created by Indian firms, if the local firms are able to produce generic versions of important 
medicines at globally competitive rates. There are however, many reasons analyzed in this 
study, that may not work in favour of indigenous pharmaceutical firms in Bangladesh that 
are seeking to capitalize on the Doha extension until 2016. 
The survey, most importantly, points out to the link between incentives for learning and 
competitiveness of the sector as a whole. As the analysis in this section shows, a 
protective local policy regime that was initially intended to boost local manufacture of 
drugs and enhance access to medicines in the local market, seems to be creating 
disincentives for the local firms to technologically upgrade their production and enhance 
competitiveness. The local pharmaceutical sector is presently focusing extensively on 
retaining the gains that accrue from their dominant position in the domestic market. This 
narrow focus, attenuated by the policy environment, fails to create appropriate incentives 
for firms to strategically invest in acquiring reverse engineering skills required for 
production of APIs. Apart from protecting local firms from extensive foreign competition, 
there is a lack of scientific and physical infrastructure support, which can also be traced to 
insufficient policy emphasis, and the relatively small domestic market does not provide 
the requisite economies of scale, which are all important factors for API skills 
development. If the local firms are to transition gradually into a competitive sector even 
within the highly competitive global generics market, their acquisition of such skills is 
essential. Industrial policy for the sector will need to resolve this paradox of creating 
appropriate incentives for technological upgrading within firms, failing which merely 
extending the TRIPS deadline will not help realize the potential of the sector. 
A sectoral lens allows for in-depth investigation of general concepts (Evans, 1995), and 
the disaggregated sector characteristics elaborated in this study create an important basis 
for thinking about the relevance of institutional incentives within the pharmaceutical 
sector in Bangladesh. Institutions play a key role in production efficiency and hence, there 
is a need to address the pre-eminence of learning institutions for creating sustained mid-
term or long-term economic growth. These institutions, as laid out in the introduction of 
this study, can either be formal or informal, coded in terms of unofficial attitudes (Rodrik, 
2003) and pre-existing cultural and social arrangements that shape the behavior of agents 
in the absence of good formal institutions for exchange.  
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Modest changes in institutional arrangements and official attitudes towards the economy 
can often produce large payoffs (Rodrik, 2003, p. 16). But these changes are contextual 
and flow from the specific needs of the knowledge system in consideration.  In the case of 
Bangladesh, an analysis of the institutional incentives for pharmaceutical innovation, as 
conducted by this study drives home two essential points. Firstly, it endorses the point on 
weak or ineffective domestic knowledge systems in least developed countries, the 
disjuncture between public sector research and commercialization of products and stresses 
the relevance of concerted policy effort to build science, technology and innovation 
institutions for economic development. Secondly, and more importantly though, it raises a 
larger question regarding the institutional framework in Bangladesh, which can perhaps be 
extended to other LDCs as well. This relates to the role of market incentives in the 
normally export-oriented, pharmaceutical sector. Why are competitive pressures of global 
exports not fostering these linkages locally, despite the obvious gains?  Competitive 
market pressures do not seem to work in the case of Bangladesh due to the institutional 
setting, where even well-intended policy and market incentives fail to enhance patterns of 
interaction and learning needed for innovation. Firms seem to be more interested in 
retaining their incumbent advantages by lobbying for static policies, rather than pushing 
concertedly for dynamic growth-oriented models. Mistrust and lack of representation of 
consumer welfare are key features of interpersonal interactions and the policy landscape. 
Most of these factors inhibit even the role of competitive market pressures in fostering 
welfare-maximizing collaborations, and can be summed up as ‘negative’ institutions 
(Evans, 1995; North 1990). The informal and (the few) formal institutions for innovation 
in the country create ample scope for capture by a few, to the detriment of the larger 
population. The survey found numerous instances where firms work around well-
intentioned policies to find informal mechanisms that help them to retain their profits, to 
the detriment of the economy and technological progress at large. This is a key finding for 
national policy bodies and international agencies trying to build innovation capacity in 
Bangladesh. This implies, for example, that within the current policy landscape, direct 
industry support to the pharmaceutical sector will not help to reduce the negative public 
health impacts, in the absence of other policy interventions that target unfair business 
models and doctor-pharmacy-industry linkages. Donor agencies and international bodies 
need to focus on how policy-relevant interventions can minimize the inefficiencies of the 
informal institutional structures that promote such rent-seeking, to move towards 
increased production efficiency and consumer welfare. 
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In the main, strategic policy support that targets consumer welfare (in terms of greater 
access to medicines both locally and globally) is key to enhancing the performance of the 
pharmaceutical sector. Incremental innovation that will make the local firms competitive 
within the global generics sector will require technological upgrading activities and 
investment in the creation of API skills. Important policy-relevant recommendations to 
boost the competitiveness of the sector can be broken up into three main fields-regulatory 
framework, innovation capacity and common services- and these are provided below. 
1. Policy assistance that seeks to enhance the competitiveness of the sector needs to focus 
on: 
a. An integrated approach to innovation and design of sectoral initiatives that 
promote human skills development of relevance to the sector, as well as improved 
coordination between the various components (especially public research and 
industry) in the domestic knowledge system;  
b. Reducing the dependencies (which are also the cause for major inefficiencies) 
between medical practice, research and product commercialization in the 
pharmaceutical sector (that presently extend well into the performance of the 
health sector);  
c. Helping Bangladesh develop concrete innovation incentives for the sector that 
could work hand-in-hand with IPRs to reduce its potential negative impacts on 
access to technologies for the sector;  
d. Help enhance capacity of the local intellectual property office, in order to be able 
to document data on patent applications and grants transparently and accountably; 
and lastly,  
e. Help forge liaisons between local and foreign firms that focus on technological 
upgrading and innovative capacity of the sector.  
 
2. Policy assistance on the regulatory framework should focus on: 
a. Assisting the formulation of GMP compliant standards for the pharmaceutical 
sector and establishment of bioequivalence facilities within the country; 
b. Enhancing the capacity and performance of the Drug Directorate both for 
regulatory compliance and for other services such as price control;  
c. Technical assistance to evolve a system of price control and price setting to 
enhance access to medicines in the local market;  
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d. Assisting in the creation of appropriate university accreditation system as well as 
help design academic and vocational courses to produce the right mix of skilled 
manpower for the sector;  
e. Separating the pharmaceutical sector regulations from the Ministry of Health 
functions, and on improving the recruitment patterns of the Ministry of Health. 
 
3. Policy assistance to set up common industry infrastructure should focus on: 
a. Assisting in the setting up of the API park; 
b. Accompanied by other policy efforts that aim to create common facilities for the 
sector that could function on a ‘pay-and-use’ basis, such as a central bioequivalence 
laboratory for firms wanting to branch out their exports to regulated and semi-
regulated markets. 
A key lesson for private sector approaches to building capacity from the analysis seems to 
be the relevance of operating within a broader framework of reforms that target sector-
level capacity building that also tackles the several pharmaceutical and health sector 
interfaces in the country. In the absence of such a holistic perspective, targeting individual 
firms’ for capacity building may not serve the long term goals of enhanced access to 
medicines both in the domestic and international markets. 
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ANNEXES 
ANNEX I: Pharmaceutical Biotechnology: Firms Surveyed 
Bangladeshi Pharmaceutical Firms Surveyed  
1. ACI Ltd 
2. Ambee Pharmaceuticals Ltd 
3. Orion Infusion Ltd 
4. Somatec Pharmaceuticals Ltd 
5. Square Pharmaceuticals Ltd 
6. Beximco Pharmaceuticals Ltd 
7. Incepta Pharmaceuticals Ltd 
8. Opsonin Pharma Limited 
9. The ACME Laboratories Ltd 
10. Sanofi Aventis 
11. Eskayef Ltd 
12. General Pharmaceutical Ltd 
13. Healthcare Pharmaceutical Ltd 
14. Globe Pharmaceuticals Ltd 
15. Pacific Pharmaceuticals Ltd 
16. Delta Pharma Ltd 
17. Biopharma Laboratories Ltd 
18. Navana Pharmaceuticals Ltd 
19. The Ibn Sina Pharmaceuticals Ltd 
20. Jayson Pharmaceuticals Ltd 
21. Ziska Pharmaceuticals Ltd 
22. Chemico Laboratories Ltd 
23. Nipa Pharmaceuticals Ltd 
24. Proteety Pharmaceuticals Ltd 
25. Doctor’s Chemical Works Ltd 
 
26. Rangs Pharmaceuticals Ltd 
27. Pharmdesh Laboratories Ltd 
28. Rephco Pharmaceuticals Ltd 
29. Apex Pharma Ltd 
30. Aristo Pharma Ltd 
31. Seema Pharmaceuticals Ltd 
32. Sky Lab Ltd 
33. Medimet Pharmaceuticals Ltd 
34. Popular Pharma Ltd 
35. Edruc Ltd 
36. Tropical Pharmaceuticals Ltd 
37. Peoples Pharma Ltd 
38. Ethical Drugs Ltd 
39. APC Pharmaceuticals Ltd 
40. Supreme Pharmaceutical Ltd 
41. Marks Man Pharmaceuticals 
42. Orion Infusion Ltd 
43. Amico Laboratories Ltd 
44. Renata Limited 
45. Chemist Laboratories 
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ANNEX II: Universities and Public Research Institutes Surveyed 
Bangladeshi Universities and Public Research Institutes Surveyed 
1. Dept. of Pharmacy, Rajshahi University 
2. Dept. of Genetic Engineering & 
Biotechnology, Rajshahi University 
3. Khulna Medical College Hospital  
4. Dept. of Biochemistry, Rajshahi University 
5. Manarat International University 
6. Dept. of Pharmacy, The University of Asia 
Pacific  
7. Northern University Bangladesh 
8. Dept. of Clinical Pharmacy & Pharmacology, 
Dhaka University 
9. Northern University of Bangladesh 
10. Northern International Medical College 
11. Dept. of Pharmaceutical Technology, Dhaka 
University 
12. Marks Institute of Medical Technology 
13. Govt. Unani Ayurvedic Medical College and 
Hospital  
14. Federal Homoeopathic Medical College and 
Hospital 
15. Rangpur Medical College and Hospital 
16. Ziaur Rahman Medical College 
17. Dept. of Biochemistry & Molecular Science, 
Dhaka University 
18. Sylhet M.A.G. Osmani College 
19. Dept. of Chemistry, Shahjalal University 
20. Dept. of Genetic Engineering & 
Biotechnology, Dhaka University 
 
21. Prime Asia University 
22. North South University 
23. Dept. of Biotechnology, Khulna 
University 
24. Pharmacy Discipline, Khulna University 
25. Dept. of Biotechnology, Islamic 
University. Kushtia 
26. Dept. of Pharmaceutical Chemistry, 
Dhaka University 
27. Dept. of Community Medicine, Gono 
Bishwabiddalaya 
28. Dept. of Pharmacy R&D, Gono 
Bishwabiddalaya 
29. Dept. of Pharmacy, Jahangir Nagar 
University 
30. Dept. of Microbiology, Gono 
Bishwabiddalaya 
31. Dept. of Biochemistry, Gono 
Bishwabiddalaya 
32. National Institute of Cancer Research 
Clinic 
33. Dinajpur Medical Hospital 
34. James P. Grant School of Public Health, 
BRAC University 
35. Bangladesh University 
36. Marie Stopes 
37. Dhaka Ahsania Mission Cancer Hospital 
38. National Heart Foundation 
39. International Centre for Diarrhoeal 
Disease Research, Bangladesh 
(ICDDR,B) 
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ANNEX III: Hospitals Surveyed 
Bangladeshi Hospitals Surveyed 
1. Badda General Hospital 
2. Japan Bangladesh Friendship Hospital 
3. Naz-E-Noor Hospital Pvt. Ltd.  
4. Ahmad Medical Center Ltd.  
5. Confirm Diagnostic Ltd.  
6. Meghna Diagnostic Pvt. Ltd 
7. Ahsania Mission Cancer Hospital 
8. National Heart Foundation Hospital 
and Research Institute 
9. Dr. Azmal Hospital Ltd.  
10. Gulshan Maa O Shishu Clinic Ltd.  
11. Asia Medical Services Ltd.  
12. ICH of Shishu Hospital Shishu 
Sasthya Foundation 
13. Dhaka Dental College and Hospital 
14. Rohima Maternity Hospital 
15. Mirpur Adhunic Hospital Ltd.  
16. Al-Rajhi Hospital Pvt. Ltd.  
17. Upasham Health Complex Pvt. Ltd.  
18. Al-Sami Hospital Pvt. Ltd.  
19. Module General Hospital 
20. National Institute of Cancer Research 
and Hospital 
21. Brighton Hospital and Diagnostic 
Center 
22. Nirupom Hospital 
23. Asian Cardiac and General Hospital 
24. Samorita Hospital Ltd.  
25. Gastro Liver Hospital and Research 
Institute Ltd.  
 
26. Al-Fateh Medical and Consultation 
Service 
27. City General Hospital and Diagnostic 
Center 
28. Health and Hope Ltd.  
29. Pedi Hope Hospital for Sick Children 
30. Popular Diagnostic Center Ltd.  
31. Delta Medical Center Ltd.  
32. Green Life Hospital Ltd.  
33. Medi Aid Hospital Ltd.  
34. South Asia Hospital Ltd.  
35. Millennium Diagnostic Center Ltd.  
36. Comfort Nursing Home (p) Ltd.  
37. Dhaka Renal Center and General 
Hospital 
38. Hitech Multicare Hospital Ltd.  
39. MARKS Hospital and SARC Health 
Care Center 
40. Pan Pacific Hospital 
41. Lab Aid Cardiac Hospital 
42. General Medical Hospital 
43. Euro Bangla Heart Hospital Ltd.  
44. National Chest Diseases Hospital 
45. Medinova Medical Service Ltd.  
46. Salvation Specialized Hospital and 
Research Ltd.  
47. Mirpur General Hospital Pvt. Ltd.  
48. Parkway General Hospital Ltd.  
49. Marie Stopes 
50. ICDDR, B 
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ANNEX IV. Field Research Interviewees  
Category and Company/Institution Name Department/Faculty 
INDUSTRY 
- Chemical  
               - Advanced Chemical Industries Ltd.   - M. Mohibuz Zaman, Chief Operating Officer, Pharma 
               - BASF - Masudur Rashid, Manager 
                         - Fine & Intermediate Chemicals - Saria Sadique, Chairman & Managing Director 
- Pharmaceutical  
              - Aristopharma, Ltd.  - M. A. Hassan, Chairman & Managing Director 
              - Delta Pharma, Ltd.  - Dr. M. Omar Faruque, Managing Director 
              - Eskayef Bangladesh Ltd.  - Mohammad Mostafa Hassan, Business Planning & Procurement Manager 
              - Healthcare Pharmaceuticals Ltd.  - Md. Halimuzzaman, Executive Director 
              - Jayson Pharmaceuticals Ltd.  - Md. Salimullah, Managing Director 
              - Rangs Pharmaceuticals Ltd.  - A. S. M. Habibur Rahman, Vice President & Director 
                       - Production Operations - Amanullah Chowdhury, Executive Vice President 
              - Square Pharmaceuticals Ltd.  - Md. Nawabur Rahman, Assistant General Manager 
 - Parvez Hashim, Executive Director Operations 
                       - Quality Operations - Jayanta Datta Gupta, Manager 
 - Muhammadul Haque, Director Marketing 
 - Mir Mijanur Rahman, Senior Executive Pesticide 
              - The ACME Laboratories Ltd.  - Md. Lutf-e-Khoda, Assistant Sales Manager 
PROFESSIONAL ASSOCIATIONS 
BAPI 
UNIVERSITIES AND PRIVATE RESEARCH INSTITUTIONS (PRIS) 
- BRAC University  
                - James P. Grant School of Public Health - Dr. Shahaduz Zaman, Ph.D., Programme Coordinator, MPH Programme 
 - Nasima Selim, Research Associate 
                         - Social & Medical Anthropology - Sabina Faiz Rashid, Ph.D., Assistant Profesor 
- Centre for Health and Population Research (ICDDR,B) - David A. Sack, MD, Executive Director 
 - Mohammed A. Salam, Director Clinical Sciences Division 
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               - External Relations & Institutional Development ERID - Armana Ahmed, MBA, Fund & Institutional Development Officer 
 - Mohsena Hassan, Public Relations Officer 
- Jahangirnagar University  
                         - Department of Pharmacy - M. Slahuddin Bhuiya, Lecturer 
 - Abdullah Faruque, Associate Professor and Chairman 
 - Dr. Md. Sohel Rana, Associate Professor & Chairman 
 - Dr. Pijus Saha 
 - Md. Ehsanul Hoque Mazumder 
                         - Department of Microbiology - Md. Salequl Islam, Lecturer 
 - Dr. Ali Azam Talukder 
                         - Department of Zoology - Abu Faiz Md. Aslam 
                         - Faculty of Biological Sciences - Prof. M. Shahabuddin K Choudhuri, Dean 
- State University of Bangladesh - Prof. Dr. Ilyas Dhami, Vice Chancellor (Designate) 
- University of Dhaka          
               - Faculty of Pharmacy - Dr. Mohammad Abdur Rashid, Dean 
 - Ilyas Dhami 
                         - Dept. of Clinical Pharmacy & Pharmacology - Bilkis Begum, Associate Professor 
 - Dr. Abul Hasnat, Associate Professor & Chairman 
 - Dr. Seheli Parveen 
 - Bilkin Begun  
 - Farida Begun  
                         - Dept. of Pharmaceutical Chemistry - Dr. Muhammad Amjad Hossain, Professor & Chairman 
 - Dr. Mohammad Mehedi Masud, Associate Professor  
 - Dr. Shaila Kabir, Assistant Professor 
 - Dr. Md. Khalid Hossain, Assistant Professor 
 - Dr. Md. Aslam Hossain 
 - Dr. Md. Shah Amran, Assistant Professor 
 - Md. Gias Uddin, Lecturer 
 - Mohhamad Rashdul Haque, Lecturer 
 - Dr. M. A. Mazid, Assistant Professor 
                         - Dept.  of Pharmaceutical Technology - Dr. Sitesh C. Bachar, Professor 
 - Eva R. Kabir, Assistant Professor 
 - Dr. Md. Selim Reza, Professor 
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 - Prof. A. B. M. Faroque, Chairman 
 - Muhammad Rashedul Islam, Lecturer 
 - Mohammad Abul Kalam Azad, Lecturer  
                         - Dept. of Genetic Engineering & Biotechnology - Mohammed Nazmul Ahsan, Lecturer 
NON-GOVERNMENTAL ORGANIZATIONS (NGOS) 
- Health, Education & Economic Development (HEED Bangladesh) - M. D. Faruque Sikder, Director Finance 
 - M. G. Dostogir Harun, Program Coordinator (Government Program) 
GOVERNMENT OF BANGLADESH 
- Ministry of Industries  
              - Dept. of Patents, Designs & Trademarks - Mesbah Uddin, Registrar 
              - Office of Copyrights - Mr. Mohmadul Hasan, Registrar Copyrights 
- Directorate of Drug Administration - Prof. Dr. Md. Habibur Rahman, Director 
- Institute of Public Health - Dr. Md. Moyez Uddin, Director 
               - Antisera Section - Momena Shirin, Specialist in Preventive & Social Medicine 
- Public Health Institute - Mokabir U. Ahmed, Drug Testing Laboratory 
OTHERS 
- Metropolital Medical Centre Ltd.  - Prof. M.A. Zaman, Professor & Head of Cardiology BM Medical College 
- World Intellectual Property Organisation (WIPO) - Kifle Shenkuru 
                - Least Developed Countries Division - Md. Daniul Islam 
                - Traditional Knowledge Division & Life Sciences  
                   Programme 
- Antony Taubman, Director & Head Global IP Issues Division 
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Annex V. Suggestions by the Faculty of Pharmacy to improve Quality of Education, 
University of Dhaka, Bangladesh 
 
Submitted to author by Faculty on 20 April 2007 
 
 
1. Establishment of National Institute of Pharmaceutical Biotechnology:  This will play a 
key role for the development and formulation of vaccines, protein and peptide drugs, 
oligoneucleotides (e.g. antisense) and other biotech products. 
 
2. Establishment of a Referral / Appellate Drug Testing Laboratory: A central drug testing 
laboratory should be established following WHO framed guidelines where in vitro and in vivo 
tests for different formulations will be conducted.  
 
3. Establishment of Pharmacokinetic and Bioequivalence Laboratory: Pharmacokinetic as 
well as bioequivalent data [Area under the curve (AUC), Time to reach maximum plasma 
concentration (tmax), Maximum plasma concentration (Cmax), Elimination half life (t1/2), 
Elimination rate constant (Kel), Mean residence time (MRT) and other statistical analysis for 
bioequivalence and pharmacokinetic studies ] will help Bangladeshi pharmaceutical companies 
to export their finished products in developed countries by meeting regulatory requirements of 
the respective Drug Administration of that country. Furthermore, this type of work will enrich 
our technological know-how and develop a national pharmacokinetic research laboratory for 
conducting pharmacokinetic and bioequivalence tests not only to meet the local requirement 
but also for exporting pharmaceuticals to different countries.  
 
4. Setting up Food and Nutraceuticals Testing Laboratory:  This will ensure the quality and 
safety profiles of foods, food supplements and nutraceuticals as well as healthy population. 
 
5. Exchange Program: Joint/collaborative research/training among different universities 
should be conducted which will help develop technology transfer and enrichment of know-
how. Through this program both faculty and students will be benefited. 
 
6. Establishment of Clinical Research Organization (CRO). CRO not only will conduct 
clinical trials but also will ensure clinical data management, quality assurance, regulatory 
affairs, medical monitoring, investigator recruitment and contract, grant management, central 
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randomization, patient recruitment, and statistics/report writing on behalf of different national 
and multinational pharmaceutical companies or academic institutions with their collaborations. 
7. Laboratory Infrastructure Development: Development of biotechnology laboratory and 
ensuring instrumental facilities in pharmacy faculty will promote biotechnology research in 
Bangladesh. 
 
8. Establishment of National Herbal Research Centre: This will ensure standardization, 
validation and evaluation of safety and efficacy of herbal drugs and formulations. As 
Bangladesh is a good repository of medicinal plants the proposed center will benefit not only 
the mass population of our country but also will attract international collaboration. 
 
9. Workshop or Training Program: Workshops as well as training program should be 
conducted with the support of donor agencies to help develop know-how of pharmacy 
graduates in Bangladesh. 
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